EBS – Emergent BioSolutions Inc.
EBS — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
17.82
Margin Of Safety %
71
Put/Call OI Ratio
0.19
EPS Next Q Diff
EPS Last/This Y
-0.46
EPS This/Next Y
-0.29
Price
7.94
Target Price
12
Analyst Recom
1
Performance Q
-37.21
Upside
36.1%
Beta
2.35
Ticker: EBS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | EBS | 8.12 | 0.29 | 1.51 | 13703 |
| 2026-03-02 | EBS | 8.98 | 0.35 | 0.10 | 14284 |
| 2026-03-03 | EBS | 8.92 | 0.36 | 1.61 | 13946 |
| 2026-03-04 | EBS | 8.77 | 0.38 | 3.03 | 14168 |
| 2026-03-05 | EBS | 8.44 | 0.35 | 0.13 | 13836 |
| 2026-03-06 | EBS | 8.28 | 0.35 | 0.21 | 13862 |
| 2026-03-09 | EBS | 8.36 | 0.34 | 0.08 | 14149 |
| 2026-03-10 | EBS | 8.4 | 0.34 | 0.16 | 14204 |
| 2026-03-11 | EBS | 8.19 | 0.34 | 0.09 | 14326 |
| 2026-03-12 | EBS | 8.13 | 0.34 | 9.42 | 14317 |
| 2026-03-13 | EBS | 8.13 | 0.34 | 8.07 | 14317 |
| 2026-03-17 | EBS | 8.1 | 0.35 | 0.13 | 14408 |
| 2026-03-18 | EBS | 8 | 0.32 | 0.44 | 14119 |
| 2026-03-19 | EBS | 8.08 | 0.32 | 36.00 | 14127 |
| 2026-03-20 | EBS | 8.18 | 0.31 | 0.17 | 14081 |
| 2026-03-23 | EBS | 8.05 | 0.21 | 0.04 | 8258 |
| 2026-03-24 | EBS | 8.02 | 0.20 | 0.05 | 8835 |
| 2026-03-25 | EBS | 8.2 | 0.19 | 0.04 | 9036 |
| 2026-03-26 | EBS | 8.09 | 0.19 | 0.00 | 9062 |
| 2026-03-27 | EBS | 7.93 | 0.19 | 0.26 | 9129 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | EBS | 8.14 | 120.0 | - | 2.05 |
| 2026-03-02 | EBS | 8.99 | - | - | 4.02 |
| 2026-03-03 | EBS | 8.92 | - | - | 0.52 |
| 2026-03-04 | EBS | 8.77 | - | - | 0.52 |
| 2026-03-05 | EBS | 8.44 | - | - | 0.52 |
| 2026-03-06 | EBS | 8.28 | - | - | 0.52 |
| 2026-03-09 | EBS | 8.36 | -135.2 | - | 0.52 |
| 2026-03-10 | EBS | 8.40 | -135.2 | - | 0.52 |
| 2026-03-11 | EBS | 8.19 | -135.2 | - | 0.52 |
| 2026-03-12 | EBS | 8.12 | -135.2 | - | 0.52 |
| 2026-03-13 | EBS | 8.06 | -135.2 | - | 0.52 |
| 2026-03-17 | EBS | 8.09 | -135.2 | - | 0.52 |
| 2026-03-18 | EBS | 8.00 | -135.2 | - | 0.52 |
| 2026-03-19 | EBS | 8.07 | -135.2 | - | 0.52 |
| 2026-03-20 | EBS | 8.18 | -135.2 | - | 0.52 |
| 2026-03-23 | EBS | 8.05 | -135.2 | - | 0.52 |
| 2026-03-24 | EBS | 8.01 | -135.2 | - | 0.52 |
| 2026-03-25 | EBS | 8.20 | -135.2 | - | 0.52 |
| 2026-03-26 | EBS | 8.09 | -135.2 | - | 0.52 |
| 2026-03-27 | EBS | 7.94 | -135.2 | - | 0.52 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | EBS | -3.81 | 4.13 | 17.56 |
| 2026-03-02 | EBS | -3.81 | 4.87 | 17.56 |
| 2026-03-03 | EBS | -3.81 | 4.87 | 17.56 |
| 2026-03-04 | EBS | -3.86 | 4.87 | 17.81 |
| 2026-03-05 | EBS | -3.86 | 4.87 | 17.81 |
| 2026-03-06 | EBS | -3.86 | 4.87 | 17.81 |
| 2026-03-09 | EBS | -3.85 | 4.82 | 17.81 |
| 2026-03-10 | EBS | -3.85 | 4.82 | 17.81 |
| 2026-03-11 | EBS | -3.86 | 4.82 | 18.04 |
| 2026-03-12 | EBS | -3.86 | 4.82 | 18.04 |
| 2026-03-13 | EBS | -3.86 | 4.82 | 18.04 |
| 2026-03-17 | EBS | -3.86 | 4.89 | 18.04 |
| 2026-03-18 | EBS | -3.86 | 4.89 | 18.04 |
| 2026-03-19 | EBS | -3.86 | 4.89 | 18.04 |
| 2026-03-20 | EBS | -3.86 | 4.89 | 18.04 |
| 2026-03-23 | EBS | -3.86 | 4.86 | 18.04 |
| 2026-03-24 | EBS | -3.86 | 4.86 | 18.04 |
| 2026-03-25 | EBS | -3.86 | 4.86 | 17.82 |
| 2026-03-26 | EBS | -3.86 | 4.86 | 17.82 |
| 2026-03-27 | EBS | -3.86 | 4.86 | 17.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.25
Avg. EPS Est. Next Quarter
0.11
Insider Transactions
-3.86
Institutional Transactions
4.86
Beta
2.35
Average Sales Estimate Current Quarter
160
Average Sales Estimate Next Quarter
181
Fair Value
13.55
Quality Score
74
Growth Score
44
Sentiment Score
39
Actual DrawDown %
91.6
Max Drawdown 5-Year %
-98.4
Target Price
12
P/E
9.56
Forward P/E
PEG
P/S
0.55
P/B
0.79
P/Free Cash Flow
2.62
EPS
0.83
Average EPS Est. Cur. Y
0.52
EPS Next Y. (Est.)
0.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
7.08
Relative Volume
0.67
Return on Equity vs Sector %
-17.3
Return on Equity vs Industry %
2.9
EPS 1 7Days Diff
0.5
EPS 1 30Days Diff
0.52
EBIT Estimation
◆
EBS
Healthcare
$7.93
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
33
Range 1M
13.9%
Sup Dist
0.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-66%
EPS NY
0%
52W%
39.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+0.4% upside
Upside
+0.4%
Quality
74
MoS
71%
Emergent BioSolutions Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 900
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
EBS
Latest News
—
Caricamento notizie per EBS…
stock quote shares EBS – Emergent BioSolutions Inc. Stock Price stock today
news today EBS – Emergent BioSolutions Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EBS – Emergent BioSolutions Inc. yahoo finance google finance
stock history EBS – Emergent BioSolutions Inc. invest stock market
stock prices EBS premarket after hours
ticker EBS fair value insiders trading